PSMA-PET SUVmean Predictive of Favorable Response to 177Lu-PSMA-617 Than Cabazitaxel in mCRPC


According to findings from a biomarker analysis of the phase 2 TheraP trial, mean standardized uptake value of PSMA-PET predicted favorable responses to 177Lu-PSMA-617 compared with cabazitaxel in patients with metastatic castration-resistant prostate cancer.

Mean standardized uptake value (SUVmean) of prostate-specific membrane antigen (PSMA) appeared to be a predictive biomarker for response to 177Lu-PSMA-617 (Pluctivo) vs cabazitaxel (Jevtana) in patients with metastatic castration-resistant prostate cancer (mCRPC), while high FDG-PET metabolic tumor volume (MTV) was associated with worse responses in both arms, according to data from the phase 2 TheraP trial (NCT03392428).

With a median follow-up of 18.4 months, 35% (n = 35/99) of patients who received 177Lu-PSMA-617 and 30% (n = 30/101) of those who received cabazitaxel had high PSMA-PET uptake, defined as a SUVmean of 10 or more. The PSA response rate for patients with a SUVmean of 10 or more receiving 177Lu-PSMA-617 and cabazitaxel, respectively, was 91% (95% CI, 76%-98%) vs 47% (95% CI, 29%-65%). For patients with a SUVmean of less than 10, the PSA response rates were 52% (95% CI, 39%-64%) vs 32% (95% CI, 22%-45%), respectively.

The multicenter, open-label, randomized phase 2 TheraP trial was conducted across 11 hospitals in Australia and enrolled a total of 200 patients with mCRPC following treatment with docetaxel (Taxotere) who were suitable to receive cabazitaxel. A total of 101 patients received a 20 mg/m2 dose of cabazitaxel intravenously every 3 weeks for up to 10 treatment cycles, and 99 patients were assigned to receive a starting dose of intravenous 177Lu-PSMA-617 at 8.5 GBq every 6 weeks for up to 6 cycles. The dose was then decreased by 0.5 GBq every cycle down to a minimum of 6.0 GBq.

Patients 18 years and older were eligible to enroll on the trial if they had adequate hematological, renal, and liver function, as well as an ECOG performance status of 0 to 2. The primary end point was PSA response rate, which was defined as the proportion of patients with a PSA reduction of at least 50% from baseline. Secondary end points included radiographic progression-free survival (rPFS) and PSA PFS.

At baseline, the mean PSMA-PET MTV for patients in the cabazitaxel and 177Lu-PSMA-617 cohorts, respectively, was 949 mL and 1082 mL. The mean PSMA-PET SUVmax was 57 and 66, and the PSMA-PET SUVmean was 9.3 and 9.7 across each respective cohort. Moreover, the mean FDG-PET MTV was 219 mL and 187 mL, the mean FDG-PET SUVmax was 11 in both respective arms. The FDG-PET SUVmean was 4.36 and 4.42 across each respective cohort. The percentage of patients who had a FDG MTV of 200 mL or more was 30% in the cabazitaxel arm and 30% in the 177Lu-PSMA-617 arm.

The PSA response rate across both treatment cohorts was 38% (95% CI, 26%-52%) for patients with an FDG-PET MTV of 200 mL or more and 56% (95% CI, 48%-65%) for patients with an FDG-PET MTV of less than 200 mL (odds ratio, 0.44; 95% CI, 0.23-0.84; P = .035).

In terms of rPFS rates in patients treated with 177Lu-PSMA-617 vs cabazitaxel, the HR was 0.46 (95% CI, 0.25-0.84) for those with a PSMA-PET SUVmean of at least 10 and 0.85 for those with a PSMA-PET SUVmean of less than 10 (95% CI, 0.59-1.24). Results were comparable in the PSA PFS analysis in patients with a PSMA-PET SUVmean of at least 10 (HR, 0.45; 95% CI, 0.25-0.80) and those with a PSMA-PET SUVmean of less than 10 (HR, 0.77; 95% CI, 0.53-1.12). Notably, patients who had a FDG-PET MTV 200 mL or greater also tended to have a worse rPFS (HR, 1.79; 95% CI, 1.28-2.52; P = .0008) and PSA PFS outcome (HR, 1.44; 95% CI, 1.03-2.02; P = 0.031).


Buteau JP, Martin AJ, Emmett L, et al. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. Lancet Oncol. 2022;23:1389-1397. doi:10.1016/S1470-2045(22)00605-2

Related Videos
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Financial constraints and a lack of education among some patients and providers must be addressed to improve the real-world use of certain prostate cancer therapies, says Neeraj Agarwal, MD.
Novel anti-PSMA monoclonal antibody rosopatamab is capable of carrying a bigger payload of radiation particles, which may potentially reduce doses for patients with prostate cancer, says Neeraj Agarwal, MD.
Findings from recent studies support the use of artificial intelligence-based tools in the context of radiation therapy for patients with localized prostate cancer, according to Neeraj Agarwal, MD.
Germline testing may elucidate important mutations in patients with metastatic prostate cancer who may be eligible to receive treatment with PARP inhibitors, according to Neeraj Agarwal, MD.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Artificial intelligence programs may help introduce new care strategies that minimize the risk of adverse effects in patients with prostate cancer, according to Wayne G. Brisbane, MD.
Related Content